Elevated plasma apolipoprotein E levels in people living with HIV : Associations with biomarkers and HIV-specific risk factors
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: Apolipoprotein E (apoE) plays a crucial role in cholesterol metabolism, and high levels of apoE in plasma are associated with cardiovascular disease and all-cause mortality. We aimed to assess if HIV is independently associated with high plasma apoE and to determine HIV-related risk factors for high plasma apoE.
METHODS: We included 661 people with HIV (PWH) from the Copenhagen Comorbidity in HIV (COCOMO) study with available measurement of plasma apoE. COCOMO participants were frequency matched 1:1 on age and sex with controls from the Copenhagen General Population Study. High plasma apoE was defined as levels above the 90th percentile (66.2 mg/L). The association between HIV and high plasma apoE was assessed using logistic regression models. Among PWH, both linear and logistic regression models were used to determine HIV-specific risk factors for high plasma apoE.
RESULTS: Mean age was 52 years and 89 % were male. Median plasma apoE was 49.0 mg/L in PWH and 43.3 mg/L in controls, p < 0.001. HIV was associated with higher plasma apoE after adjusting for potential confounders, including triglycerides (odds ratio 2.14 [95 % CI: 1.39-3.29], p < 0.001). In PWH, higher plasma apoE was associated with a previous AIDS-defining condition in linear models before adjustment for triglycerides and integrase strand transfer inhibitor use in fully adjusted linear models.
CONCLUSIONS: PWH had higher plasma apoE than controls even after adjusting for triglycerides. Further studies are needed to elucidate the clinical impact of high plasma apoE in PWH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
Atherosclerosis - 390(2024) vom: 01. März, Seite 117457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reimer Jensen, Anne Marie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
APOE |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.atherosclerosis.2024.117457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367909669 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367909669 | ||
| 003 | DE-627 | ||
| 005 | 20240311232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2024.117457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM367909669 | ||
| 035 | |a (NLM)38301603 | ||
| 035 | |a (PII)S0021-9150(24)00017-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reimer Jensen, Anne Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elevated plasma apolipoprotein E levels in people living with HIV |b Associations with biomarkers and HIV-specific risk factors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Apolipoprotein E (apoE) plays a crucial role in cholesterol metabolism, and high levels of apoE in plasma are associated with cardiovascular disease and all-cause mortality. We aimed to assess if HIV is independently associated with high plasma apoE and to determine HIV-related risk factors for high plasma apoE | ||
| 520 | |a METHODS: We included 661 people with HIV (PWH) from the Copenhagen Comorbidity in HIV (COCOMO) study with available measurement of plasma apoE. COCOMO participants were frequency matched 1:1 on age and sex with controls from the Copenhagen General Population Study. High plasma apoE was defined as levels above the 90th percentile (66.2 mg/L). The association between HIV and high plasma apoE was assessed using logistic regression models. Among PWH, both linear and logistic regression models were used to determine HIV-specific risk factors for high plasma apoE | ||
| 520 | |a RESULTS: Mean age was 52 years and 89 % were male. Median plasma apoE was 49.0 mg/L in PWH and 43.3 mg/L in controls, p < 0.001. HIV was associated with higher plasma apoE after adjusting for potential confounders, including triglycerides (odds ratio 2.14 [95 % CI: 1.39-3.29], p < 0.001). In PWH, higher plasma apoE was associated with a previous AIDS-defining condition in linear models before adjustment for triglycerides and integrase strand transfer inhibitor use in fully adjusted linear models | ||
| 520 | |a CONCLUSIONS: PWH had higher plasma apoE than controls even after adjusting for triglycerides. Further studies are needed to elucidate the clinical impact of high plasma apoE in PWH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a APOE | |
| 650 | 4 | |a Antiretroviral treatment | |
| 650 | 4 | |a Apolipoprotein E | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Human immunodeficiency virus | |
| 650 | 4 | |a Triglycerides | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Apolipoproteins E |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 700 | 1 | |a Frikke-Schmidt, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Gelpi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Knudsen, Andreas D |e verfasserin |4 aut | |
| 700 | 1 | |a Benfield, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Nordestgaard, Børge G |e verfasserin |4 aut | |
| 700 | 1 | |a Afzal, Shoaib |e verfasserin |4 aut | |
| 700 | 1 | |a Biering-Sørensen, Tor |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Susanne Dam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atherosclerosis |d 1970 |g 390(2024) vom: 01. März, Seite 117457 |w (DE-627)NLM000087394 |x 1879-1484 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2024 |g day:01 |g month:03 |g pages:117457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.atherosclerosis.2024.117457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2024 |b 01 |c 03 |h 117457 | ||